Nutriband Inc. (NASDAQ:NTRB) Short Interest Down 20.9% in March

Posted by Bonnie Powley on Mar 31st, 2025

Nutriband Inc. (NASDAQ:NTRB – Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 222,300 shares, a decrease of 20.9% from the February 28th total of 281,200 shares. Currently, 4.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 201,300 shares, the short-interest ratio is presently 1.1 days.

Nutriband Stock Performance

Shares of Nutriband stock opened at $6.26 on Monday. The business’s 50 day moving average price is $7.02 and its 200 day moving average price is $5.85. The company has a market cap of $69.52 million, a price-to-earnings ratio of -8.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.83 and a current ratio of 4.96. Nutriband has a one year low of $3.20 and a one year high of $11.78.

Wall Street Analyst Weigh In

Separately, Noble Financial initiated coverage on shares of Nutriband in a report on Wednesday, January 22nd. They issued an “outperform” rating and a $13.00 price objective for the company.

Check Out Our Latest Stock Report on Nutriband

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nutriband stock. Haven Private LLC acquired a new position in shares of Nutriband Inc. (NASDAQ:NTRB – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,561 shares of the company’s stock, valued at approximately $54,000. Haven Private LLC owned about 0.10% of Nutriband at the end of the most recent quarter. Institutional investors and hedge funds own 19.70% of the company’s stock.

Nutriband Company Profile

(Get Free Report)

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.